ValueTheMarkets Logo
Stock Market Review for the Retail Investor

Cardiol Therapeutics

(TSX:CRDL | OTCQX:CRTPF | FRA:CT9)

Cardiol Therapeutics Inc. is a clinical-stage biotechnology company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). The Company’s lead product, CardiolRx™, is a pharmaceutically produced extra strength oral cannabidiol formulation that is currently entering a Phase II/III outcomes study in hospitalized patients testing positive for the COVID-19 virus. This potentially registrational trial is designed to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce mortality and major cardiovascular events in 422 COVID-19 patients who have a prior history of, or risk factors for, CVD, and to investigate the influence CardiolRx has on key markers of inflammatory heart disease.

Pharma’s $7.2 Billion CBD Acquisition Could Trigger New Biotech Boom

Pharma’s $7.2 Billion CBD Acquisition Could Trigger New Biotech Boom

CARDIOL THERAPEUTICS INC. (TSX:CRDL | OTCQX:CRTPF | FRA:CT9) Giant $7.2 Billion Acquisition Validates CBD With Jazz Pharmaceuticals announcing they plan to acquire GW Pharmaceuticals for USD$7.2 billion, the pharma industry just validated a revolutionary treatment....